Terence Friedlander is an Oncology physician affiliated with University of California, San Francisco. OpenAlex indexes 406 publications with 7,819 citations (h-index 35); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
505 Parnassus Ave Moffitt M1286 Mail Stop 1270
Ucsf Medical Center
San Francisco, CA 941430001
Telephone
415-885-7276Provider last certified this registry record 30 Apr 2026.
Clinical trials
- Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma
Sponsor: University of California, San Francisco
- Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer
Sponsor: University of California, San Francisco
- Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer
Sponsor: Terence Friedlander, MD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202510 payments$11,696openpaymentsdata.cms.gov ↗
- Samsung Bioepis Co., Ltd.Program year20255 payments
- Astellas Pharma US IncProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
43.7%Cytochrome P450 17A1 Inhibitor22.9%Abiraterone Acetate100%Part D<11 patientsAndrogen Receptor Inhibitor20.8%Xtandi100%Part D<11 patientsMetabolism & gastrointestinal
22.9%Corticosteroid11.4%Prednisone100%Part D≥16 patientsSerotonin-3 Receptor Antagonist6.5%Ondansetron Hcl100%Part D≥12 patients+ 1 more class in this area
Anti-infectives
9.8%Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor9.8%Lamivudine Hbv100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Emmanuelle Waubant, MD
University of California, San Francisco
Peter Ganz, MD
University of California, San Francisco
Joel Palefsky, MD
University of California, San Francisco
Peter Hunt, MD
University of California, San Francisco
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”